Point mutations in the α2 domain of HLA-A2.1 define a functionally relevant Interaction with TAP

Current Biology

Volumn 6, Issue 7, 1996, Pages 873-883

  Lewis, Jonathan W ^a   Neisig, Anne ^b   Neefjes, Jacques ^b   Elliott, Tim ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0030198868     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9822(02)00611-5     Document Type: Article

References (42)

1. Townsend A, Bastin J, Gould K, Brownlee G, Andrew M, Coupar B, Boyle D, Chan S, Smith G: Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J Exp Med 1988, 168:1211-1224.
2. Moore MW, Carbone FR, Bevan MJ: Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988, 54:777-785.
3. Heemels MT, Ploegh H: Generation, translocation and presentation of MHC class I-restricted peptides. Annu Rev Biochem 1995, 64:463.
4. Deverson EV, Gow IR, Coadwell WJ, Monaco JJ, Butcher GW, Howard JC: MHC class II region encoding proteins related to the multidrug resistance family of transmembrane transporters. Nature 1990, 348:738-741.
5. Trowsdale J, Hanson I, Mockridge I, Beck S, Townsend A, Kelly A: Sequences encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters. Nature 1990, 348:741-744.
6. Spies T, Bresnahan M, Bahram S, Arnold D, Blanck G, Mellins E, et al.: A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature 1990, 348:744-747.
7. Roelse J, Gromme M, Momburg F, Hammerling G, Neefjes J: Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling. J Exp Med 1994, 180:1591-1597.
8. Elliott T, Willis A, Cerundolo V, Townsend A: Processing of major histocompatibility class I-restricted antigens in the endoplasmic reticulum. J Exp Med 1995, 181:1481-1491.
9. Snyder HL, Yewdell JW, Bennink J: Trimming of antigenic peptides in an early secretory compartment. J Exp Med 1994, 180:2389-2394.
10. Elliott T, Cerundolo V, Elvin J, Townsend A: Peptide-induced conformational change of the class I heavy chain. Nature 1991, 351:402-406.
11. Degen E, Williams DB: Participation of a novel 88-kD protein in the biogenesis of murine class I histocompatibility molecules. J Cell Biol 1991, 112:1099-1115.
12. Hochstenbach F, David V, Watkins S, Brenner MB: Endoplasmic reticulum resident protein of 90 kilodaltons associates with the T-and B-cell antigen receptors and major histocompatibility complex antigens during their assembly. Proc Natl Acad Sci USA 1992, 89:4734-4738.
13. Suh WK, Cohen-Doyle MF, Fruh K, Wang K, Peterson PA, Williams DB: Interaction of MHC class I molecules with the transporter associated with antigen processing. Science 1994, 264:1322.
14. Ortmann B, Androlewicz MJ, Cresswell P: MHC class I/β-2 microglobulin complexes associate with TAP transporters before peptide binding. Nature 1994, 368:864-867.
15. Anderson K, Cresswell P, Gammon M, Hermes J, Williamson A, Zweerink H: Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis. J Exp Med 1991, 174:489-492.
16. Townsend A, Ohlen C, Bastin J, Ljunggren HG, Foster L, Karre K: Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 1989, 340:443-448.
17. Cerundolo V, Alexander J, Anderson K, Lamb C, Cresswell P, McMichael A, et al.: Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature 1990, 345:449-452.
18. Moots RJ, Matsui M, Pazmany L, McMichael AJ, Frelinger JA: A cluster of mutations in HLA-A2 alpha 2 helix abolishes peptide recognition by T cells, Immunogenetics 1991, 34:141-148.
19. Lombardi G, Matsui M, Moots R, Aichinger G, Sidhu S, Batchelor R, et al.: Structural relationship between HLA-A2-restricted and anti-A2 allospecific T-cell recognition: Analysis by mutation of the codons for polymorphic and conserved residues. Transplant Proc 1991, 23:446-448.
20. Matsui M, Moots RJ, Warburton RJ, Peace-Brewer AL, Quinn DG, McMichael AJ, Frelinger JA: Genetic evidence for difference between intracellular and extracellular peptides in Influenza A matrix peptide-specific CTL recognition. J Immunol 1995, 154:1088-1096.
21. DeMars R, Chang CC, Shaw C, Reitnauer J, Sondel PM: Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B lymphoblastoid cells. Reduced proliferative responses of autologous and allogenic T cells to mutant cells that have decreased expression of class I antigens. Hum Immunol 1984, 11:77-82.
22. Ceman S, Rudersdorf R, Long EO, DeMars R: MHC class II deletion mutant expresses normal levels of transgene encoded class II molecules that have abnormal conformation and impaired antigen presentation ability. J Immunol 1992, 149:754-761.
23. Riberdy JM, Cresswell P: The antigen-processing mutant T2 suggests a role for MHC-linked genes in class II antigen presentation. J Immunol 1992, 148:2586-2590.
24. Wei ML, Cresswell P: HLA-A2 molecules in an antigen processing mutant cell contain signal sequence-derived peptides. Nature 1992, 356:443-446.
25. Henderson RA, Michel H, Sakaguchi K, Shabanowitz J, Appella EF, Hunt D, Engelhard E: HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 1992, 255:1264-1266.
26. Elvin J, Potter C, Elliott T, Cerundolo V, Townsend A: A method to quantify binding of unlabeled peptides to class I MHC molecules and detect their allele specificity. J Immunol Methods 1993, 158: 161-171.
27. Zweerink HJ, Gammon MC, Utz U, Sauma SY, Harrer T, Hawkins JC, et al.: Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J Immunol 1993, 150:1763-1771.
28. Kleijmeer MJ, Kelly A, Geuze HJ, Slot JW, Townsend A, Trowsdale J: Location of MHC-encoded transporters in the endoplasmic reticulum and cis-Golgi. Nature 1992, 357:342-344.
29. Neisig A, Wubbolts R, Zang X, Melief C, Neefjes J: The specificity of TAP-class I interactions displays two routes of peptide loading of MHC class I molecules. J Immunol 1996, in press.
30. Zemmour J, Little A, Schendel DJ, Parham P: The HLA-A,B 'negative' mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. J Immunol 1992, 148:1941-1948.
31. Lee N, Malacko NR, Ishitani A, Chen M, Bajorath J, Marquardt H, Geraghty DE: The membrane-bound and soluble forms of HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association. Immunity 1995, 3:591-600.
32. Rubocki RJ, Connolly JM, Hansen TH, Melvold RW, Kim BS, Hildebrand WH, Martinko J: Mutation at amino acid position 133 of H-2Dd prevents β2m association and immune recognition but not surface expression. J Immunol. 1991, 146:2352-2357.
33. Carreno BM, Solheim JC, Harris M, Stroynowski I, Connolly JM, Hansen TH: TAP associates with a unique class I conformation, whereas calnexin associates with multiple class I forms in mouse and man. J Immunol 1995, 155:4726-4733.
34. Greenwood R, Shimizu Y, Sekhon GS, DeMars R: Novel allelespecific, post-translational reduction in HLA class I surface expression in a mutant human B-cell line. J Immunol 1994, 153:5525-5536.
35. Grandea AG III, Androlewicz MJ, Athwal RS, Geraghty DE, Spies T: Dependence of peptide binding by MHC class I molecules on their interaction with TAP. Science 1995, 270:105-108.
36. Edwards PAW, Smith CM, Neville AM, O'Hare MJ: A human-human hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line. Eur J Immunol 1982, 12:641-648.
37. Parham P, Brodsky FM: Partial purification and some properties of BB7.2 a cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum Immunol 1981, 3:277-299.
38. Parham P, Barnstable CJ, Bodmer WF: Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,-B,-C antigens. J Immunol 1979, 123:342-349.
39. Morrison J, Elvin J, Latron F, Gotch F, Moots R, Strominger JL, McMichael A: Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes. Eur J Immunol 1992, 22:903-907.
40. Tsomides TJ, Walker BD, Eisen HN: An optimal viral peptide recognized by CD8+ T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. Proc Natl Acad Sci USA 1991, 88:11276-11280.
41. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel M, Sevilir N, et al.: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992, 255:1261-1263.
42. Neefjes J, Breur-Vriesendorp BS, van Seventer GA, Ivanyi P, Ploegh HL: An improved biochemical method for the analysis of HLA class I antigens. Definition of new subtypes. Hum Immunol 1986, 16:169-181.